Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2006 2
2007 2
2008 1
2010 3
2011 1
2013 2
2014 2
2015 2
2016 5
2017 3
2018 4
2019 6
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Recent advances in autosomal-dominant polycystic kidney disease.
Rangan GK, Tchan MC, Tong A, Wong AT, Nankivell BJ. Rangan GK, et al. Intern Med J. 2016 Aug;46(8):883-92. doi: 10.1111/imj.13143. Intern Med J. 2016. PMID: 27553994 Review.
Identifying and integrating patient-centred perspectives in clinical trials is also being advocated. This review will provide an update on recent advances in the clinical management of ADPKD....
Identifying and integrating patient-centred perspectives in clinical trials is also being advocated. This review will provide an upda …
Polycystic kidney disease: new horizons and therapeutic frontiers.
Czarnecki PG, Steinman TI. Czarnecki PG, et al. Minerva Urol Nefrol. 2013 Mar;65(1):61-8. Minerva Urol Nefrol. 2013. PMID: 23538311 Review.
Furthermore, proliferative and tissue patterning responses to mTOR, STAT, CDK and wnt signaling play an important role in various aspects of cystogenesis and represent further targets for therapy. Only a limited amount of clinical evidence from randomized controlled …
Furthermore, proliferative and tissue patterning responses to mTOR, STAT, CDK and wnt signaling play an important role in various aspects of …
Drug discovery for polycystic kidney disease.
Sun Y, Zhou H, Yang BX. Sun Y, et al. Acta Pharmacol Sin. 2011 Jun;32(6):805-16. doi: 10.1038/aps.2011.29. Acta Pharmacol Sin. 2011. PMID: 21642949 Free PMC article. Review.
Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease.
Xu Y, Li A, Wu G, Liang C. Xu Y, et al. Curr Gene Ther. 2017;17(1):43-49. doi: 10.2174/1566523217666170510152808. Curr Gene Ther. 2017. PMID: 28494735 Review.
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in the clinic. The predominant clinical manifestation is bilateral and progressive cysts formation in the kidneys, impairs normal renal parenchyma, and ultimately l …
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in the clinic. The predominant …
New treatments for autosomal dominant polycystic kidney disease.
Chang MY, Ong AC. Chang MY, et al. Br J Clin Pharmacol. 2013 Oct;76(4):524-35. doi: 10.1111/bcp.12136. Br J Clin Pharmacol. 2013. PMID: 23594398 Free PMC article. Review.
Since its first description over 200 years ago, ADPKD has been considered an untreatable condition and its management is limited to blood pressure reduction and symptomatic treatment of disease complications. Results of the recently reported TEMPO 3/4 trial thus represent …
Since its first description over 200 years ago, ADPKD has been considered an untreatable condition and its management is limited to blood pr …
Methodological issues in clinical trials of polycystic kidney disease: a focused review.
Iliuta IA, Kitchlu A, Pei Y. Iliuta IA, et al. J Nephrol. 2017 Jun;30(3):363-371. doi: 10.1007/s40620-016-0358-6. Epub 2016 Nov 17. J Nephrol. 2017. PMID: 27858251 Review.
In this review, we discuss the methodological pitfalls of high-profile clinical interventional trials for ADPKD which have been published since 2009. ...Implementing these lessons learned from the published trials will greatly enhance the robustness and validity of future …
In this review, we discuss the methodological pitfalls of high-profile clinical interventional trials for ADPKD which have been publi …
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Yu ASL, et al. Kidney Int. 2019 May;95(5):1253-1261. doi: 10.1016/j.kint.2018.12.023. Epub 2019 Mar 4. Kidney Int. 2019. PMID: 30922668 Free PMC article.
Thus, GFR decline in ADPKD is nonlinear, and its trajectory throughout adulthood can be predicted from a single measurement of kidney volume. These models can be used for clinical prognostication, clinical trial design, and patient selection for clinical …
Thus, GFR decline in ADPKD is nonlinear, and its trajectory throughout adulthood can be predicted from a single measurement of kidney volume …
32 results